References
- Balfour J, Clissod S. Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs 1990; 39: 575–6
- Bonomi L, Marchini G, De Franco I, Perfetti S, Gregorio M. Bendazac lysine salt in treatment of cataract a controlled study. Curr Ther Res Clin Exp 1983; 33: 727–32
- Ballesteros J, Badosa A, Usandizaga I, Armengual M. Hepatotoxicity due to bendazac [letter]. Lancet 1987; 2: 1030–1
- Prieto de Paula J, Cancelo P, Villamandos V, Sanchez A. Hepatitis tóxica por bendazaco [letter]. Med Clin (Barc) 1993; 20: 48
- Bruguera H, Martinez M, Benarroch J, Rodes J. Hepatotoxicity due to bendazac. Gastroenterol Hepatol 1993; 16: 357–9
- Mackay IR. Introduction by drugs of hepatitis and antibodies to cell organelles: significance and interpretation. Hepatology 1985; 5: 590
- Furet Y, Mitman EH, Breteau M, Bertrand J. Hepatitis due to nonesteroidal anti-inflammatory agents. Ann Gastroenterol Hepatol 1985; 1–431
- Maddrey WC, Boitnott JK. Drug induced chronic liver disease. Gastroenterology 1987; 72: 1348
- Nuki G. Pain control and the use of non-steroidal analgesic antiinflammatory drugs. Br Med Bull 1990; 1: 262–78
- Cancelo P, Prieto de Paula JM, De la Cueva JA, Velasco A. Hepatitis por droxicam [letter]. Med Clin (Barc) 1992; 99: 238–9
- Rovie R, Escourrou J, Campistron S. The pharmacokinetics of bendazac lysine and 5-hydroxybendazac its main metabolite in patients with hepatic cirrhosis. Eur J Clin Pharmacol 1988; 35: 391–6
- Kaplowitz N, Yee Awt, Simon FR, Solz A. Drug-induced hepatotoxicity. Ann Intern Med 1986; 104: 826–39
- Menckes CJ. Renal and hepatic effects of NSAIDs in the elderly. Scand. J Rheumatol 1989; 83: 11–3, Suppl
- James OFW. Drugs and the ageing liver. J Hepatol 1985; 1: 431
- Kroman-Andersen H, Pedersen A. Reported adverse reactions to and consumption of nonesteroidal anti-inflammatory drugs in Denmark over a 17 year period. Dan Med Bull 1988; 2: 187–92